JD HEALTH
06618
JD-SW
09618
BEKE-W
02423
TRIP.COM-S
09961
NTES-S
09999
(Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | (Q6)Jun 30, 2019 | (FY)Dec 31, 2018 | (FY)Dec 31, 2017 | |
---|---|---|---|---|---|
Cash flow from operating activities | |||||
Earning before tax | 709.25%24.42B | 576.03%21.05B | --3.02B | -71.56%3.11B | --10.95B |
Profit adjustment | |||||
Interest (income) - adjustment | -55.32%-1.03B | -46.17%-1.42B | ---665.84M | -503.86%-971.28M | ---160.85M |
Interest expense - adjustment | -41.50%138.54M | -44.94%467.92M | --236.82M | 32.57%849.9M | --641.09M |
Investment loss (gain) | -40.72%-1.14B | -17.79%-1.67B | ---810.36M | -321.67%-1.42B | ---335.58M |
Attributable subsidiary (profit) loss | -17.51%1.03B | 103.82%3.11B | --1.25B | -27.14%1.53B | --2.09B |
Impairment and provisions: | -8.42%207.95M | 565.35%474.89M | --227.08M | 148.07%71.37M | ---148.48M |
-Other impairments and provisions | -8.42%207.95M | 565.35%474.89M | --227.08M | 148.07%71.37M | ---148.48M |
Revaluation surplus: | 309.77%3.03B | 93.56%-1.11B | --739.05M | -1,695.77%-17.28B | --1.08B |
-Other fair value changes | 309.77%3.03B | 93.56%-1.11B | --739.05M | -1,695.77%-17.28B | --1.08B |
Asset sale loss (gain): | 96.85%-16.12M | -497.65%-524.71M | ---511.93M | -599.62%-87.8M | ---12.55M |
-Loss (gain) from sale of subsidiary company | 97.45%-12.82M | -572.67%-503.36M | ---503.36M | -576.84%-74.83M | ---11.06M |
-Loss (gain) on sale of property, machinery and equipment | 61.51%-3.3M | -64.68%-21.35M | ---8.57M | -768.32%-12.96M | ---1.49M |
Depreciation and amortization: | 38.42%1.41B | 74.32%2.31B | --1.02B | 37.29%1.32B | --963.37M |
-Depreciation | 38.42%1.41B | 74.32%2.31B | --1.02B | 37.29%1.32B | --963.37M |
Financial expense | -29.71%440.72M | 53.24%1.25B | --626.98M | 180.12%816.89M | --291.62M |
Exchange Loss (gain) | -107.86%-4.89M | 323.53%46.26M | --62.23M | -151.21%-20.69M | --40.41M |
Special items | 25.80%2.61B | 28.12%4.83B | --2.08B | 19.79%3.77B | --3.15B |
Operating profit before the change of operating capital | 328.14%31.09B | 446.97%28.81B | --7.26B | -144.77%-8.3B | --18.55B |
Change of operating capital | |||||
Accounts receivable (increase)decrease | 60.69%-1.5B | -40.31%-5.05B | ---3.81B | -768.72%-3.6B | --538.51M |
Accounts payable increase (decrease) | 828.32%8.25B | -45.89%5.2B | --888.82M | 42.56%9.62B | --6.75B |
prepayments (increase)decrease | -299.44%-9.79B | -4.01%-5.04B | ---2.45B | 21.18%-4.84B | ---6.15B |
Special items for working capital changes | -287.27%-538.92M | 33.65%-6.33B | ---139.16M | -685.78%-9.53B | ---1.21B |
Cash from business operations | 1,468.10%27.51B | 205.64%17.6B | --1.75B | -190.18%-16.66B | --18.48B |
Other taxs | -52.83%-1.44B | 48.24%-1.44B | ---940.26M | -14.21%-2.78B | ---2.44B |
Interest received - operating | 104.11%935.38M | 176.61%1.1B | --458.27M | 293.84%396.92M | --100.78M |
Net cash from operations | 2,022.56%27.01B | 190.61%17.26B | --1.27B | -218.02%-19.05B | --16.14B |
Cash flow from investment activities | |||||
Interest received - investment | -32.00%15.18M | -77.78%22.72M | --22.32M | 2,092.09%102.26M | --4.67M |
Loan receivable (increase) decrease | -99.11%12.38M | 219.99%1.39B | --1.38B | -4.81%-1.16B | ---1.1B |
Sale of fixed assets | -53.03%4.83M | 137.33%34.06M | --10.27M | -21.92%14.35M | --18.38M |
Purchase of fixed assets | 90.10%-220.86M | 25.85%-2.09B | ---2.23B | -137.12%-2.81B | ---1.19B |
Selling intangible assets | ---- | 6,383.33%12.06M | --156K | --186K | ---- |
Purchase of intangible assets | 56.38%-54.04M | -9,746.82%-12.86B | ---123.88M | 30.03%-130.59M | ---186.63M |
Sale of subsidiaries | ---- | ---- | ---- | ---- | ---867K |
Acquisition of subsidiaries | 96.76%-96.88M | -149.83%-3.02B | ---2.99B | -4,384.00%-1.21B | --28.22M |
Recovery of cash from investments | -16.69%11.97B | -32.93%27.84B | --14.36B | 246.53%41.51B | --11.98B |
Cash on investment | 2.23%-12.69B | 40.13%-38.84B | ---12.98B | -142.21%-64.87B | ---26.78B |
Net cash from investment operations | 58.09%-1.07B | 3.66%-27.51B | ---2.55B | -65.73%-28.55B | ---17.23B |
Net cash before financing | 2,130.89%25.94B | 78.47%-10.25B | ---1.28B | -4,279.68%-47.6B | ---1.09B |
Cash flow from financing activities | |||||
New borrowing | 8.98%20.23B | -65.83%22.88B | --18.57B | 91.51%66.96B | --34.96B |
Refund | 44.51%-13.51B | 27.90%-41.04B | ---24.34B | -149.64%-56.92B | ---22.8B |
Issuing shares | 394.96%277.06M | -84.05%12.22B | --55.98M | --76.57B | ---- |
Interest paid - financing | 10.73%-753.58M | -1.91%-1.64B | ---844.13M | -50.88%-1.61B | ---1.06B |
Dividends paid - financing | ---339.92M | ---- | ---- | ---- | ---525.87M |
Other items of the financing business | -125.28%-330.48M | 194.18%11.45B | --1.31B | -5,278.32%-12.16B | ---226.07M |
Net cash from financing operations | 206.13%5.58B | -94.68%3.87B | ---5.26B | 604.13%72.84B | --10.35B |
Effect of rate | 406.80%123.2M | -62.91%140.68M | --24.31M | 1,108.43%379.33M | ---37.62M |
Net Cash | 582.42%31.52B | -125.25%-6.37B | ---6.53B | 172.65%25.24B | --9.26B |
Begining period cash | -13.55%39.77B | 125.74%46B | --46B | 82.65%20.38B | --11.16B |
Cash at the end | 80.84%71.41B | -13.55%39.77B | --39.49B | 125.74%46B | --20.38B |
Cash balance analysis | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.